20135 ⎘
Medicinal preparations characterised by special physical form; Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
Biguanide compositions and methods of treating metabolic disorders
#902Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
#903Abuse-proofed dosage form
#904Compositions comprising extract and preparation method and uses thereof
#905Methods and compositions for treating hyperhidrosis
#906Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
#907Syndecan-4 proteoliposomes for enhanced cutaneous wound healing and minimized inflammatory immune response
#908Peptide nucleic acid of subgroup J avian leukosis virus and uses thereof
#909GASTRIC ACID MODULATORS FOR ORAL DELIVERY OF PEPTIDES AND PROTEINS
#910Solid oral formulation of fenretinide
#911Pharmaceutical compositions for the treatment of
#912ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS
#913Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
#914Heterocyclic compounds with working memory enhancing activity
#915Compositions comprising extract and preparation method and uses thereof
#916Compositions and Methods for Treating an Infection
#917PHARMACEUTICAL COMPOSITIONS
#918ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF
#919APPARATUS AND METHOD FOR GENERATING HYDROGEN-CONTAINING LIQUID
#920Devices and methods for preparing gastroretentive dosage forms
#921Medicine delivery and animal management systems
#922COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE
#923Method of administering amantadine prior to a sleep period
#924AMANTADINE COMPOSITIONS AND METHODS OF USE
#925Method of administering amantadine prior to a sleep period
#926Methods of manufacturing oral dosage forms
#927Methods of treating opiate dependency and preventing non-oral opiate abuse among opiate addicts
#928NANOPARTICULATE FORMULATION COMPRISING A mPGES-1 INHIBITOR
#929FORMULATIONS COMPRISING 2-AMINO-2-[2-(4-OCTYLPHENYL)ETHYL]PROPANE-1,3-DIOL
#930Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
#931Nano- and micro-sized particles of 20-camptothecin or derivative thereof and pharmaceutical compositions containing same, and treatment of cancers therewith
#932Extended-release topiramate capsules
#933Metoprolol sustained-release composition and preparation method thereof
#934Tamper resistant oral opioid agonist formulations
#935Modified release coated capsules
#936Accordion pill comprising levodopa for an improved treatment of Parkinson's Disease symptoms
#937EXTENDED RELEASE COMPOSITIONS OF CARVEDILOL PHOSPHATE
#938Solid oral dosage form of lipophilic compounds
#939CARBIDOPA/LEVODOPA GASTRORETENTIVE DRUG DELIVERY
#940Timed, pulsatile release systems
#941Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
#942TAMPER-RESISTANT DOSAGE FORM WITH IMMEDIATE RELEASE AND RESISTANCE AGAINST SOLVENT EXTRACTION
#943Pharmaceutical formulation containing gelling agent
#944PHARMACEUTICAL COMPOSITION CAPABLE OF ACCELERATED PENETRATION INTO AFFECTED AREA
#945Method for delivering pramlintide into a lumen of the intestinal tract using a swallowable drug delivery device
#946Pharmaceutical formulation
#947EXTENDED RELEASE COMPOSITIONS OF AN AMINOALKYL NITRATE
#948Pharmaceutical compositions resistant to abuse
#949Pharmaceutical composition and administrations thereof
#950Low Dose Pharmaceutical Composition
#951Apparatus and process for encapsulating capsules or other solid dosage forms within capsules
#952ACCORDION PILL COMPRISING LEVODOPA FOR AN IMPROVED TREATMENT OF PARKINSON'S DISEASE SYMPTOMS
#953Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
#954Composition that relieves heartburn, GERD and hangovers
#955Compositions for treatment of attention deficit hyperactivity disorder
#956Modified release coated capsules
#957Devices and Methods for Weight Control and Weight Loss
#958Compositions and methods for reducing overdose
#959Fixed Dose Combination for Pain Relief Without Edema
#960PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS
#961Compositions for treatment of attention deficit hyperactivity disorder
#962Oral pharmaceutical dosage forms of budesonide
#963Protecting oral overdose with abuse deterrent immediate release formulations
#964Use of NK-1 receptor antagonists in pruritus
#965Pharmaceutical dosage form for immediate release of an indolinone derivative
#966Pharmaceutical formulation containing gelling agent
#967BIOPHARMA APPLICATION OF MICELL TECHNOLOGY
#968Extended Release Dosage Form Comprising Cyclobenzaprine Hydrochloride
#969Extended Release Dosage Form Comprising Cyclobenzaprine Hydrochloride
#970Extended Release Dosage Form Comprising Cyclobenzaprine Hydrochloride
#971Positive pressure capsules and method of manufacturing the same
#972Swallowable drug delivery device and methods of drug delivery
#973PHARMACEUTICAL COMPOSITIONS COMPRISING 40 - O - ( 2 - HYDROXY) ETHYL - RAPAMYCIN
#974Methods for delivering insulin preparations into a lumen of the intestinal tract using a swallowable drug delivery device
#975MANUFACTURING METHOD FOR SOFTGEL CAPSULE CONTAINING SOLID AND LIQUID FORMULATIONS AS CORE INGREDIENT
#976Method for delivering exenatide into a lumen of the intestinal tract using a swallowable drug delivery device
#977Implantable drug delivery device
#978UNSATURATED FATTY ACID ABSORPTION ACCELERATOR
#979Enterically coated cysteamine, cystamine and derivatives thereof
#980Capsule dosage form of metoprolol succinate
#981Method and apparatus for forming delivery devices for oral intake of an agent
#982Acid resistant banding solution for acid resistant two piece hard capsules
#983INGESTIBLE CAPSULE
#984Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
#985Pharmaceutical formulation containing gelling agent
#986Pharmaceutical formulation containing gelling agent
#987Chemosensory receptor ligand-based therapies
#988Nutritional Supplement and Method of Administering the Same
#989PHARMACEUTICAL FORM FOR COMBATING CHEMICAL SUBMISSION OF A MEDICAMENT
#990Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
#991DEVICES AND METHODS FOR TREATING THE GASTROINTESTINAL SYSTEM
#992Oral delivery system for hemoglobin based oxygen carriers
#993Pharmaceutical compositions
#994Tamper resistant immediate release capsule formulation comprising tapentadol
#995MICROFABRICATED NANOPORE DEVICE FOR SUSTAINED RELEASE OF THERAPEUTIC AGENT
#996Beta-lactam cholesterol absorption inhibitors
#997COLON VITAMIN
#998Treating pain in patients with hepatic impairment
#999Pharmaceutical compositions of dimethyl fumarate
#1000MODIFIED AND IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE
#1001HYBRID HOLLOW MICROCAPSULE, SCAFFOLD FOR SOFT TISSUE INCLUDING SAME, AND METHODS OF PREPARING SAME
#1002COMPOSITION AND METHOD FOR AIDING SLEEP
#1003ORAL PHARMACEUTICAL COMPOSITION OF METHYLERGONOVINE
#1004Organic Compounds
#1005Multimicroparticulate pharmaceutical forms foe oral administration
#1006Oral dosage forms for delivery of therapeutic agents
#1007Enterically coated cysteamine, cystamine and derivatives thereof
#1008Delayed Release Cysteamine Bead Formulation, and Methods of Making and Using Same
#1009ALL NATURAL, NON-TOXIC SUBLINGUAL DRUG DELIEVERY SYSTEMS
#1010Enterically coated cysteamine, cystamine and derivatives thereof
#1011Pharmaceutical composition containing clomipramine and preparation method therefor
#1012Low-Dose Stable Formulations of Linaclotide
#1013Tamper-resistant dosage form with immediate release and resistance against solvent extraction
#1014Low Dose Topiramate/Phentermine Composition and Methods of Use Thereof
#1015TAMPER-RESISTANT FIXED DOSE COMBINATION PROVIDING FAST RELEASE OF TWO DRUGS FROM PARTICLES
#1016TAMPER-RESISTANT DOSAGE FORM WITH IMMEDIATE RELEASE AND RESISTANCE AGAINST SOLVENT EXTRACTION
#1017TAMPER-RESISTANT FIXED DOSE COMBINATION PROVIDING FAST RELEASE OF TWO DRUGS FROM DIFFERENT PARTICLES
#1018TAMPER-RESISTANT FIXED DOSE COMBINATION PROVIDING FAST RELEASE OF TWO DRUGS FROM PARTICLES AND A POWDER
#1019Controlled release dosage form for once daily administration of dimethyl fumarate
#1020CRUSH-RESISTANT SOLID ORAL DOSAGE FORM
#1021Stable liquid filled hard capsule comprising beta-hydroxy-beta methylbutyric acid
#1022PHARMACEUTICAL COMPOSITIONS COMPRISING AN ACTIVE AGENT
#1023Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
#1024Multi-compartment dosage form articles
#1025MULTI-PARTICULATE DRUG DELIVERY SYSTEM
#1026Use of NK-1 receptor antagonists in pruritus
#1027Shell-forming compositions for soft capsules and soft capsules
#1028Cromolyn derivatives and related methods of imaging and treatment
#1029Controlled Release Doxycycline
#1030Floating gastric retentive dosage form
#1031Treating pain in patients with hepatic impairment
#1032Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
#1033METHODS AND SYSTEMS FOR IMPROVED BIOAVAILABILITY OF ACTIVE PHARMACEUTICAL INGREDIENTS INCLUDING ESOMEPRAZOLE
#1034Dosage form articles
#1035Treating pain in patients with hepatic impairment
#1036Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
#1037COMPOSITIONS FOR THE TREATMENT OF CNS-RELATED CONDITIONS
#1038Quinine compounds, and optical isomers, preparation method and medical use thereof
#1039Controlled release pharmaceutical formulations of nitazoxanide
#1040Device and method for reducing calorie intake
#1041COMPOSITIONS FOR THE TREATMENT OF CNS-RELATED CONDITIONS
#1042SUSTAINED-RELEASE COMPOSITIONS COMPRISING TOPIRAMATE AND AN ALKALIZER
#1043Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
#1044Composition comprising an organic liquid diluent and a specific hydroxyalkyl methylcellulose
#1045Pharmaceutical compositions for the treatment of
#1046DELIVERY CAPSULE WITH THRESHOLD RELEASE
#1047Controlled release hydrocodone formulations
#1048Pharmaceutical Formulation
#1049MONOMETHYLFUMARATE PRODRUG COMPOSITIONS
#1050STABLE SOLID UNITS AND METHODS OF MAKING THE SAME
#1051MULTI-LAYER CAPSULE AND MANUFACTURE METHOD THEREOF
#1052Formulations and Dosage Forms of Oxidized Phospholipids
#1053Bile acid recycling inhibitors for treatment of obesity and diabetes
#1054Abuse-proofed oral dosage form
#1055COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE COMPOUNDS AND METHOD FOR THEIR PREPARATION
#1056Implantable medical devices for extended release of therapeutic agents
#1057Accordion pill comprising levodopa for an improved treatment of Parkinson's disease symptoms
#1058Method for treating intestinal fibrosis
#1059Fumarate ester pharmaceutical compositions
#1060Semi-permeable encapsulation system with tapered conduits for diabetes reversal
#1061Carbidopa/levodopa gastroretentive drug delivery
#1062Compositions for treatment of attention deficit hyperactivity disorder
#1063Crush resistant delayed-release dosage forms
#1064NUTRACEUTICAL COMBINATION FOR PREVENTION AND TREATMENT OF TYPE 2 DIABETES
#1065Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
#1066Delayed Release Cysteamine Bead Formulation, And Methods Of Making And Using Same
#1067Pharmaceutical formulation containing gelling agent
#1068Pharmaceutical formulation containing gelling agent
#1069Pharmaceutical formulation containing gelling agent
#1070Pharmaceutical formulation containing gelling agent
#1071Pharmaceutical formulation containing gelling agent
#1072Enterically coated cysteamine, cystamine and derivatives thereof
#1073Pharmaceutical formulation containing gelling agent
#1074Pharmaceutical formulation containing gelling agent
#1075Pharmaceutical formulation containing gelling agent
#1076Method for delivery of somatostatin into a lumen of the intestinal tract
#1077Method and composition for treating alzheimer-type dementia
#1078EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS OF METOPROLOL
#1079Capsule dosage form of metoprolol succinate
#1080Compositions and methods for treating centrally mediated nausea and vomiting
#1081Multi-phase, multi-compartment, capsular delivery apparatus and methods for using same
#1082Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
#1083Curcumin solubilisate
#1084Once Daily Formulations of Tetracyclines
#1085Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
#1086Oral formulation for the treatment of cardiovascular diseases
#1087Pharmaceutical compositions
#1088Timed, pulsatile release systems
#1089CONTROLLED RELEASE OF VEGETARIAN PORE-SEALING CAPSULE IN STOMACH, DUODENUM, JEJUNUM, ILEUM AND COLON
#1090Controlled release fumarate esters
#1091Beta-lactamase formulations and uses thereof
#1092CAPSULE FORMULATION COMPRISING MONTELUKAST AND LEVOCETIRIZINE
#1093Pharmaceutical compositions of tamsulosin or salts thereof
#1094Oral pharmaceutical dosage forms
#1095Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
#1096Pharmaceutical compositions
#1097Anti-methanogenic compositions and uses thereof
#1098STABLE PHARMACEUTICAL COMPOSITIONS OF MESALAMINE
#1099Timed, pulsatile release systems
#1100Enteric coated multiparticulate composition with proteinaceous coating for improved storage stability
#1101Tamper resistant pharmaceutical formulations
#1102PULSATILE GASTRIC RETENTIVE DOSAGE FORMS
#1103COMPOSITIONS AND METHODS FOR TREATMENT IN PARKINSON'S DISEASE PATIENTS
#1104METHOD OF REDUCING SOMNOLENCE IN PATIENTS TREATED WITH TIZANIDINE
#1105Compounds to modulate intestinal absorption of nutrients
#1106L-menthol dosage forms having a proteinaceous coating for enhanced storage stability
#1107Separable capsule
#1108Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
#1109ABUSE-PROOFED ORAL DOSAGE FORM
#1110Enhanced drug delivery pill
#1111USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES
#1112Pharmaceutical Formulation Containing Gelling Agent
#1113Pharmaceutical formulation containing gelling agent
#1114DOSAGE FORM FOR CINEOLE
#1115STABLE PHARMECEUTICAL COMPOSITION OF AMLODIPINE AND BENAZEPRIL OR SALTS THEREOF
#1116Pharmaceutical formulation containing gelling agent
#1117Nested supramolecular capsules
#1118Photo-responsive macro- and micro-liquid marbles
#1119Pharmaceutical formulation containing irritant
#1120Carbidopa/levodopa gastroretentive drug delivery
#1121MULTIPARTICULATE PHARMACEUTICAL COMPOSITION COMPRISING A MULTITUDE OF TWO KINDS OF PELLETS
#1122Delayed-release formulations, methods of making and use thereof
#1123Enteric soft capsule compositions
#1124LIQUID-FILLED IMMEDIATE RELEASE SOFT GELATIN CAPSULES
#1125Pharmaceutical products
#1126HIGH DRUG LOAD PHARMACEUTICAL COMPOSITIONS WITH CONTROLLABLE RELEASE RATE AND PRODUCTION METHODS THEREOF
#1127Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
#1128GLYPISOME AS AN ENHANCER OF ANGIOGENIC GROWTH FACTOR ACTIVITY
#1129Enteric coating for soft capsule
#1130Curcumin solubilisate
#1131Composition for forming complex, complex formed therefrom, and composition for oral administration including said complex
#1132Coating Method and Materials
#1133Cell lines and their use in encapsulated cell biodelivery
#1134CAPSULE DISPENSING CONTAINER
#1135ORAL FORM, COMPRISING IMMEDIATE-RELEASE COATED PARTICLES OF AT LEAST ONE ACTIVE COMPOUND THAT ARE GRINDING-RESISTANT
#1136PHARMACEUTICALLY ACCEPTABLE DOSAGE FORM COMPRISING RELEASE OF MULTIPLE DRUGS FROM SINGLE ORAL DOSAGE FORM
#1137Capsules containing high doses of levodopa for pulmonary use
#1138Abuse deterrent immediate release coated reservoir solid dosage form
#1139Pharmaceutical compositions
#1140PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN ASSOCIATED WITH DYSMENORRHEA
#1141Compressed Tablets
#1142Solid ganaxolone compositions and methods for the making and use thereof
#1143Pharmaceutical compositions
#1144Pharmaceutical composition having reduced abuse potential
#1145Pharmaceutical Compositions
#1146Pharmaceutical compositions
#1147Pharmaceutical formulation containing gelling agent
#1148PHARMACEUTICAL COMPOSITIONS COMPRISING HYDROMORPHONE AND NALOXONE
#1149Abuse deterrent immediate release biphasic matrix solid dosage form
#1150Pharmaceutical formulation containing gelling agent
#1151Pharmaceutical Formulation Containing Gelling Agent
#1152Pharmaceutical formulation containing gelling agent
#1153Chemosensory receptor ligand-based therapies
#1154Extended-release topiramate capsules
#1155Oral dosage forms of bendamustine and therapeutic use thereof
#1156Microfabricated nanopore device for sustained release of therapeutic agent
#1157Microfabricated nanopore device for sustained release of therapeutic agent
#1158Doxycycline Formulations, and Methods of Treating Rosacea
#1159Method for delivering exenatide to a patient in need thereof
#1160Pharmaceutical formulation containing gelling agent
#1161Method of treatment of attention deficit hyperactivity disorder
#1162Oral Drug Devices and Drug Formulations
#1163SOFT ELASTIC CAPSULES CONTAINING TABLETS AND LIQUID OR SEMISOLID FILLS AND METHODS FOR THEIR MANUFACTURE
#1164Compositions for treatment of attention deficit hyperactivity disorder
#1165Tamper-resistant oral opioid agonist formulations
#1166PHARMACEUTICAL COMPOSITE CAPSULE FORMULATION COMPRISING IRBESARTAN AND HMG-COA REDUCTASE INHIBITOR
#1167ORAL FORMULATIONS OF CHEMOTHERAPEUTIC AGENTS
#1168FORMULATIONS OF FLIBANSERIN
#1169ORAL CAFFEINE DELIVERY COMPOSITION
#1170PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE
#1171PROCESS FOR MANUFACTURING DRUG DELIVERY FORMULATIONS
#1172PHARMACEUTICAL COMPOSITIONS OF MESALAMINE
#1173Modified release dosage forms of skeletal muscle relaxants
#1174Solid Dosage Form That Promotes Reliable Oral, Esophageal and GI Transit
#1175Pharmaceutical formulation containing gelling agent
#1176Tamper-resistant oral opioid agonist formulations
#1177Microfabricated nanopore device for sustained release of therapeutic agent
#1178Dissolution enhanced controlled drug delivery system for poorly water soluble drugs
#1179MULTI-LAYER CAPSULE AND MANUFACTURE METHOD THEREOF
#1180Apparatus and process for encapsulating capsules or other solid dosage forms within capsules
#1181Stabilized pharmaceutical compositions of dabigatran and process for preparation thereof
#1182Formulation of diclofenac
#1183Formulation of diclofenac
#1184Pharmaceutical formulation containing gelling agent
#1185Method for delivering pramlintide into a lumen of the intestinal tract using a swallowable drug delivery
#1186FORMULATIONS COMPRISING IBRUTINIB
#1187Multi-compartmented container
#1188FORMULATIONS
#1189Composition and method for treating neurological disease
#1190Compositions for treatment of attention deficit hyperactivity disorder
#1191Immediate Release Abuse-Deterrent Granulated Dosage Forms
#1192Orally available pharmaceutical formulation suitable for improved management of movement disorders
#1193Therapeutic delivery device
#1194COMPOSITE FORMULATION COMPRISING MULTI-UNIT SPHEROIDAL TABLET (MUST) ENCAPSULATED IN HARD CAPSULE AND METHOD FOR PREPARING SAME
#1195Modified release dosage forms of skeletal muscle relaxants
#1196Stabilized formulations of CNS compounds
#1197Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
#1198Controlled dose drug delivery system
#1199Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
#1200Abuse resistant forms of immediate release oxymorphone, method of use and method of making